肾上腺皮质癌预后较差，存在多种临床、病理和治疗变量。目前，我们缺乏预后和治疗计算器来确定辅助放化疗的生存率和疗效。我们的目的是验证一个评估预后和治疗的计算器。我们搜索了国家癌症数据库来识别 2004 年至 2020 年接受手术治疗的肾上腺皮质癌患者，并将他们随机分配到训练集 (80%) 或验证集 (20%) 中。我们分析了年龄变量；性别;查尔森合并症指数；保险状况；肿瘤大小；病理肿瘤、淋巴结和转移类别；手术切缘；以及使用化疗和放射治疗。我们使用 Cox 回归预测模型和引导系数生成数学模型来预测 5 年和 10 年总体生存率。使用曲线下面积分析评估模型的性能后，我们比较了训练集和验证集的总体生存率。对研究中纳入的 3,480 名患者进行的多变量分析显示，除性别外，所有变量均显着 (P < .05) 和纳入数学模型。训练集的 5 年和 10 年总生存率曲线下面积分别为 0.68 和 0.70，验证集的曲线下面积分别为 0.70 和 0.72。对于引导系数，5 年和 10 年总生存率分别为 6.4% 和 4.1%，高于观察到的平均值。我们的模型根据临床、病理和治疗变量预测肾上腺皮质癌患者的总生存率，并且可以协助个体化治疗。版权所有 © 2023 Elsevier Inc. 保留所有权利。

Adrenocortical carcinoma has a poor prognosis and multiple clinical, pathological, and treatment variables. Currently, we lack a prognostic and treatment calculator to determine the survival and efficacy of adjuvant chemoradiation. We aimed to validate a calculator to assess prognosis and treatment.We searched the National Cancer Database to identify patients with adrenocortical carcinoma surgically treated from 2004 to 2020 and randomly allocated them into a training (80%) or validation set (20%). We analyzed the variables of age; sex; Charlson Comorbidity Index; insurance status; tumor size; pathologic tumor, node, and metastasis categories; surgical margins; and use of chemotherapy and radiation therapy. We used Cox regression prediction models and bootstrap coefficients to generate a mathematical model to predict 5- and 10-year overall survival. After using the area under the curve analysis to assess the model's performance, we compared overall survival in the training and validation sets.Multivariable analysis of the 3,480 patients included in the study revealed that all variables were significant except sex (P < .05) and incorporated into a mathematical model. The area under the curve for 5- and 10-year overall survival was 0.68 and 0.70, respectively, for the training set and 0.70 and 0.72, respectively, for the validation set. For the bootstrap coefficients, the 5- and 10-year overall survival was 6.4% and 4.1%, respectively, above the observed mean.Our model predicts the overall survival of patients with adrenocortical carcinoma based on clinical, pathologic, and treatment variables and can assist in individualizing treatment.Copyright © 2023 Elsevier Inc. All rights reserved.